Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 1027-1037

  Talero, Elena ^a   Bolivar, Samir ^b   Ávila Román, Javier ^a   Alcaide, Antonio ^a   Fiorucci, Stefano ^c   Motilva, Virginia ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b Atlantic University   (Colombia)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

chronic inflammation; colon carcinogenesis; COX 2; cytokines; VSL 3

Indexed keywords

CYCLINE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VSL3; AUTACOID; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; GASTROINTESTINAL DYSPLASIA; HISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ULCERATIVE COLITIS; ADENOCARCINOMA; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; CHRONIC DISEASE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CHRONIC DISEASE; COLITIS, ULCERATIVE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; PROBIOTICS; PROLIFERATING CELL NUCLEAR ANTIGEN; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84929119542     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000346     Document Type: Article

References (38)

1. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145: 166-75e8.
2. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?. World J Gastroenterol. 2012;18: 3839-3848.
3. Waldner MJ, Neurath MF. Cytokines in colitis associated cancer: potential drug targets?. Inflamm Allergy Drug Targets. 2008;7:187-194.
4. Cheng J, Fan XM. Role of cyclooxygenase-2 in gastric cancer development and progression. World J Gastroenterol. 2013;19:7361-7368.
5. Dixon DA, Blanco FF, Bruno A, et al. Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res. 2013;191: 7-37.
6. Talero E, Sanchez-Fidalgo S, Villegas I, et al. Role of different inflammatory and tumor biomarkers in the development of ulcerative colitisassociated carcinogenesis. Inflamm Bowel Dis. 2011;17:696-710.
7. Arthur JC, Gharaibeh RZ, Uronis JM, et al. VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-Associated colorectal cancer. Sci Rep. 2013;3:2868.
8. Nagpal R, Kumar A, Kumar M, et al. Probiotics, their health benefits and applications for developing healthier foods: a review. FEMS Microbiol Lett. 2012;334:1-15.
9. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-Analysis of randomized controlled trials. Inflamm Bowel Dis. 2014; 20:21-35.
10. Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1140-G1149.
11. Uronis JM, Arthur JC, Keku T, et al. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis. 2011;17:289-297.
12. Dai C, Zheng CQ, Meng FJ, et al. VSL#3 probiotics exerts the antiinflammatory activity via PI3k/Akt and NF-kappaB pathway in rat model of DSS-induced colitis. Mol Cell Biochem. 2013;374:1-11.
13. Mencarelli A, Distrutti E, Renga B, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One. 2011;6:e22978.
14. Appleyard CB, Cruz ML, Isidro AA, et al. Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-Associated cancer. Am J Physiol Gastrointest Liver Physiol. 2011; 301:G1004-G1013.
15. Yeo M, Kim DK, Park HJ, et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics. 2006;6: 1158-1165.
16. Gommeaux J, Cano C, Garcia S, et al. Colitis and colitis-Associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol. 2007;27:2215-2228.
17. Okayasu I, Yamada M, Mikami T, et al. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol. 2002;17:1078-1083.
18. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14:931-968.
19. Vavassori P, Mencarelli A, Renga B, et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183:6251-6261.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
21. Scarpa M, Castagliuolo I, Castoro C, et al. Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. World J Gastroenterol. 2014;20:6774-6785.
22. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146: 1489-1499.
23. Zhu Y, Michelle Luo T, Jobin C, et al. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett. 2011;309:119-127.
24. Soo I, Madsen KL, Tejpar Q, et al. VSL#3 probiotic up regulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol. 2008;22:237-242.
25. Bassaganya-Riera J, Viladomiu M, Pedragosa M, et al. Immunoregulatory mechanisms underlying prevention of colitis-Associated colorectal cancer by probiotic bacteria. PLoS One. 2012;7:e34676.
26. Ierardi E, Principi M, Francavilla R, et al. Epithelial proliferation and ras p21 oncoprotein expression in rectal mucosa of patients with ulcerative colitis. Dig Dis Sci. 2001;46:1083-1087.
27. Takashima T, Sakata Y, Iwakiri R, et al. Feeding with olive oil attenuates inflammation in dextran sulfate sodium-induced colitis in rat. J Nutr Biochem. 2014;25:186-192.
28. Linsalata M, Russo F, Berloco P, et al. Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats. In Vivo. 2005;19:989-995.
29. Friederich P, Verschuur J, van Heumen BW, et al. Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis. Int J Colorectal Dis. 2011;26:575-582.
30. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-Alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118:560-570.
31. Wang Y, Wang K, Han GC, et al. Neutrophil infiltration favors colitisassociated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol. 2014;7:1106-1115.
32. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-Associated cancer. Cancer Cell. 2009;15:103-113.
33. Shah N, Kammermeier J, Elawad M, et al. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep. 2012;12:373-379.
34. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001; 121:580-591.
35. Di Giacinto C, Marinaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol. 2005;174: 3237-3246.
36. Ng SC, Plamondon S, Kamm MA, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010;16: 1286-1298.
37. Fratila OC, Ilias TI. COX-2 and Ki-67 immunohistochemical markers in the assessment of long-standing ulcerative colitis associated dysplasia. Rom J Morphol Embryol. 2013;54:143-149.
38. Lobo Prabhu KC, Vu L, Chan SK, et al. Predictive utility of cyclooxygenase-2 expression by colon and rectal cancer. Am J Surg. 2014; 207:712-716.